Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effects of US Bilateral Rectus Sheath Block for Laparoscopic GY Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multi-port laparoscopic gynecologic surgery~* American society of Anesthesiologists (ASA) physical status classification I-II~* Age: 21-60~Exclusion Criteria:~* Gynecologic cancer operation~* History of previous abdominal surgery~* Allergy to local anesthetics(ropivacaine)~* Opioid tolerance~* Coagulopathy~* Infection at the needle insertion site~* Difficulty to cooperating

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rectus sheath block (Type: EXPERIMENTAL): Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
- Control (Type: SHAM_COMPARATOR): Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).